Inhibition of Hsp90 Leads to Cell Cycle Arrest and Apoptosis in Human Malignant Pleural Mesothelioma

Introduction: Heat shock protein 90 (Hsp90) is an abundant molecular chaperone that mediates the maturation and stability of a variety of proteins associated with the promotion of cell growth and survival. Inhibition of Hsp90 function leads to proteasomal degradation of its mis-folded client proteins. Recently, Hsp90 has emerged as being of prime importance to the growth and survival of cancer cells and its inhibitors have already been used in phase I and II clinical trials. Methods: We investigated how 17-allylamino-17-demethoxygeldanamycin (17-AAG), a small molecule inhibitor of Hsp90, is implicated in human malignant pleural mesothelioma (MM). Results: We found that 17-AAG led to significant G1 or G2/M cell cycle arrest, inhibition of cell proliferation, and decrease of AKT, AKT1, and survivin expression in all human malignant pleural mesothelioma cell lines examined. We also observed significant apoptosis induction in all MM cell lines treated with 17-AAG. Furthermore, 17-AAG induced apoptosis in freshly cultured primary MM cells and caused signaling changes identical to those in 17-AAG treated MM cell lines. Conclusion: These results suggest that Hsp90 is strongly associated with the growth and survival of MM and that inhibition of Hsp90 may have therapeutic potential in the treatment of MM.

[1]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[2]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[3]  L. Whitesell,et al.  Altered Hsp90 function in cancer: a unique therapeutic opportunity. , 2004, Molecular cancer therapeutics.

[4]  R. Govindan,et al.  Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B , 2005, Clinical Cancer Research.

[5]  W. Sessa,et al.  Regulation of survivin function by Hsp90 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Yalcin,et al.  Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. , 2006, Lung cancer.

[7]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[8]  T G Myers,et al.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.

[9]  S. Larson,et al.  Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer , 2007, Clinical Cancer Research.

[10]  D. Hallahan,et al.  Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma , 2005, Cancer.

[11]  E. Zuhowski,et al.  Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers , 2005, Clinical Cancer Research.

[12]  O. Dalesio,et al.  Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. , 2005, Lung cancer.

[13]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[14]  Hong Zhang,et al.  Targeting multiple signal transduction pathways through inhibition of Hsp90 , 2004, Journal of Molecular Medicine.

[15]  F. Kaye,et al.  Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer , 2000, Oncogene.

[16]  N. Rosen,et al.  Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 , 2002, Oncogene.

[17]  S. Ramalingam,et al.  Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers , 2007, Clinical Cancer Research.

[18]  S. Lakhani,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Rosen,et al.  Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function* , 2002, The Journal of Biological Chemistry.

[20]  W. Richards,et al.  Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. , 2004, The Journal of thoracic and cardiovascular surgery.

[21]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[22]  D. Taub,et al.  Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers , 2004, Cancer biology & therapy.

[23]  R. Gerner,et al.  Chemotherapy of malignant mesothelioma. , 1974, Oncology.

[24]  V. Rousson,et al.  Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[25]  D. Jablons,et al.  A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. , 2005, American journal of respiratory cell and molecular biology.

[26]  D. Hedley,et al.  Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo , 2008, Cancer Chemotherapy and Pharmacology.

[27]  A. Kamal,et al.  Therapeutic and diagnostic implications of Hsp90 activation , 2004, Trends in Molecular Medicine.

[28]  K. Camphausen,et al.  Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Jiayuh Lin,et al.  17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types. , 2005, Gynecologic oncology.

[30]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[31]  B. Krishnan,et al.  Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT , 2006, Molecular Cancer Therapeutics.

[32]  R. Bueno.  Mesothelioma clinical presentation. , 1999, Chest.

[33]  E. Butchart.  Contemporary management of malignant pleural mesothelioma. , 1999, The oncologist.

[34]  James B. Mitchell,et al.  Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. , 2003, Cancer research.

[35]  L. Grochow,et al.  Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  N. Rosen,et al.  Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. , 2001, Cancer research.

[37]  K. Uematsu,et al.  p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. , 2001, Cancer research.

[38]  H. Kindler,et al.  New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. , 2002, Seminars in oncology.

[39]  R. Arceci,et al.  Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study , 2007, Clinical Cancer Research.

[40]  Y. Wu,et al.  Overexpression of Hp95 induces G1 phase arrest in confluent HeLa cells. , 2001, Differentiation; research in biological diversity.

[41]  T. Hideshima,et al.  Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma , 2006, Clinical Cancer Research.

[42]  J Espinosa Arranz,et al.  [Malignant mesothelioma]. , 1994, Medicina clinica.

[43]  C. Hudis,et al.  Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  H. Machida,et al.  Heat shock protein 90 inhibitor 17‐allylamino‐17‐demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis , 2005, Cancer science.

[45]  L. Medeiros,et al.  Inhibition of Heat Shock Protein 90 Function by 17-Allylamino-17-Demethoxy-Geldanamycin in Hodgkin's Lymphoma Cells Down-Regulates Akt Kinase, Dephosphorylates Extracellular Signal–Regulated Kinase, and Induces Cell Cycle Arrest and Cell Death , 2006, Clinical Cancer Research.

[46]  K. Uematsu,et al.  Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. , 2002, Molecular cancer therapeutics.

[47]  E. Felip,et al.  A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  K. Uematsu,et al.  p14ARF Modulates the Cytolytic Effect of ONYX-015 in Mesothelioma Cells with Wild-type p53 , 2001 .

[49]  Timothy A. J. Haystead,et al.  The Amino-terminal Domain of Heat Shock Protein 90 (hsp90) That Binds Geldanamycin Is an ATP/ADP Switch Domain That Regulates hsp90 Conformation* , 1997, The Journal of Biological Chemistry.

[50]  S. Jhanwar,et al.  Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth , 2005, Oncogene.

[51]  Luis Moroder,et al.  Structure of TPR Domain–Peptide Complexes Critical Elements in the Assembly of the Hsp70–Hsp90 Multichaperone Machine , 2000, Cell.

[52]  S. Mandrekar,et al.  A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer , 2006, Clinical Cancer Research.